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The underlying molecular mechanisms involve in the regulation of the angiogenic process
by insulin are not well understood. In this review article, we aim to describe the
role of insulin and insulin receptor activation on the control of angiogenesis and how
these mechanisms can be deregulated in human diseases. Functional expression of
insulin receptors and their signaling pathways has been described on endothelial cells
and pericytes, both of the main cells involved in vessel formation and maturation.
Consequently, insulin has been shown to regulate endothelial cell migration, proliferation,
and in vitro tubular structure formation through binding to its receptors and activation
of intracellular phosphorylation cascades. Furthermore, insulin-mediated pro-angiogenic
state is potentiated by generation of vascular growth factors, such as the vascular
endothelial growth factor, produced by endothelial cells. Additionally, diseases such as
insulin resistance, obesity, diabetes, and cancer may be associated with the deregulation
of insulin-mediated angiogenesis. Despite this knowledge, the underlying molecular
mechanisms need to be elucidated in order to provide new insights into the role of insulin
on angiogenesis.
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INTRODUCTION
Insulin receptor(s) stimulation has pleiotropic effects on endothelial cells (Westermeier et al., 2011).
For instance, insulin induces vasorelaxation, enhances endothelial uptake of amino acids (such as
L-arginine) and increases survival and migration of endothelial cells (Dubó et al., 2016; Sobrevia
et al., 2016). These actions, combined with the capacity of insulin to enhance expression of pro-
angiogenic factors such as vascular endothelial growth factor (VEGF), as well as increase pericytes
survival and reduce anti-angiogenic protein expression, have established the role of insulin in
physiological and pathological angiogenesis (He et al., 2006).
Angiogenesis is the process by which a new blood vessel is formed from a preexisting one
(Shibuya, 2013). However, angiogenesis is only one of the mechanisms responsible for vessel
formation. Thus, other process such as vasculogenesis (in which angioblast differentiate into
endothelial cells leading to de novo vessel formation); intussusception (split of pre-existing vessels);
and vascular mimicry (tumor cell line vessels) are also present during vessel formation. In addition,
other process such as vessel differentiation into arteries (arteriogenesis) or differentiation of
progenitor endothelial cells or bone-marrow-derived cells can occur during revascularization of
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ischemic tissues. Nevertheless, since vessels nourish nearly every
cell in the body, decreased or increased angiogenesis can impact
body function. Then, angiogenesis is beneficial for tissue growth
and regeneration, but also it can enhance inflammatory response
or malignant diseases; or can contribute to cancer metastasis
leading to mortality (Cumsille et al., 2015).
Taken the last information into account, it is thought that
growth of new blood vessels in the adult -when it is needed-
occurs trough vasculogenesis, angiogenesis, and arteriogenesis
(Buschmann and Schaper, 1999; Carmeliet, 2000; Semenza,
2007). Therefore, in pathologies, when reduced blood vessel
formation is present (such as during wound healing in diabetic
patients), those normal stimuli for vessel formation can be down
regulated. Contrary, during malignant diseases (such as diabetic
retinopathy) up-regulation of those processes is expected. In
addition, pro-angiogenic signals can also resemble vasculogenesis
in diabetic retinopathy.
In this manuscript, we will review the current information
regarding insulin receptor activation, the associated intracellular
pathways and the cellular outcomes involved in insulin-mediated
angiogenesis. Also in this article, we will highlight the effect of
insulin-mediated angiogenesis in pathological conditions such as
diabetes, obesity and cancer. Despite the relevance of insulin-like
growth factor (IGF-1) and its receptors (IGFRs) to cancer, we
have intentionally omitted this topic to focus this review on the
role of insulin and insulin receptors on endothelial cells.
ANGIOGENESIS OVERVIEW
Angiogenesis is a complex process driven by endothelial and
tissue-dependent signals in which at least three sequential
steps can be identified: quiescence, activation, and resolution.
These processes have been summarized by Carmeliet and Jain
(2011) who described that, as a first step in a healthy adult,
endothelial cells are quiescent and have a long half-lives. At
this stage, endothelial cells are protected against insults by
the autocrine action of several maintenance signals including
Abbreviations: PDK-1, 3-phosphoinositide-dependent protein kinase-1; SREBP-
1, Akt-sterol regulatory element-binding protein-1; Ang, Angiopoietin; ANG-
1, Angiopoietin-1; ANGPTL, Angiopoietin-like proteins; BAD, Bcl-2-associated
death promoter; eNOS, Endothelial nitric oxide synthase; EPC, Endothelial
progenitor cells; ECM, Extracellular matrix; ERK, Extracellular signal-regulated
kinases; FGFs, Fibroblast growth factors; GDM, Gestational diabetes; HbA1c,
Glycosylated hemoglobin A1c; Grb-2, Growth factor receptor-bound protein 2;
EGFL7, Growth factor-like domain; HOMA-IR, Homeostasis model assessment
for insulin resistance; HUVEC, Human umbilical vein endothelial cell; IR,
Insulin receptor; IGF-IR, Insulin-like growth factor receptors; IGF, Insulin-
like growth factors; MAPK, Mitogen-activated protein kinase; MIRKO, Muscle-
specific insulin receptor knockout; NRP, Neuropilins; NO, Nitric oxide; NOS,
Nitric oxide synthase; PKC, Protein kinase C; PIP3, Phosphatidylinositol 3; 4;
5-trisphosphate; PI3K, Phosphoinositide 3-kinase; PLCγ1, Phospholipase Cγ1;
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proto-oncogene non-receptor tyrosine kinase; Tie, Tie receptor tyrosine kinases;
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Type 2 diabetes mellitus; VEGF, Vascular endothelial growth factor; VEGFRs,
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vascular endothelial growth factor (VEGF), angiopoietin-1
(ANG-1), fibroblast growth factors (FGFs), and Notch signaling,
as well as by paracrine signals from pericytes, a cell type that cover
mature blood vessels. Pericytes also releases pro-survival signals
and suppresses endothelium proliferation via VEGF and ANG-1
Therefore, all vessels in a healthy adult exhibit a non-proliferating
monolayer of endothelial cells covered by pericytes.
Once pro-angiogenic signals released by subrogating tissue
(which include VEGF, ANG-2, FGF, chemokines, inflammatory,
and tumor mediators) are sensed for endothelial cells, a series of
mechanisms are initiated in order to generate new blood vessels.
Initially, pericytes are detached from blood vessel walls and
liberate themselves from the basement membrane by proteolytic
degradation. Then, endothelial cells loose their junctions leading
to dilatation of vessels, increase in the vascular permeability
and protein extravasation. Therefore, protein exudates form a
provisional extracellular matrix (ECM) scaffold that serve as a
platform for endothelial cell migration and formation of nascent
vessels (Armulik et al., 2005; Carmeliet and Jain, 2011). To
further build a tube and prevent endothelial migration in a
chaotic form, a process is required by which one endothelial
cells, known as the “tip cells,” becomes selected to lead cell
migration in the presence of pro-angiogenic signals, whereas
neighbors cells assume subsidiary positions forming “stack cells.”
Specialization in tip and stack cells is not a random process,
cells are selected according to their levels of VEGF receptors
(VEGFRs) expression, in which VEGFR type 2 (VEGFR2) is
mainly present in “tip cells,” whereas VEGFR1 is expressed
on “stack cells” (Gerhardt et al., 2003; Suchting et al., 2007).
In addition, tip cells are equipped with filopodia to sense
environmental guidance cues such as ephrins and semaphorins,
whereas stalk cells release molecules such as epidermal growth
factor-like domain (EGFL7) into the ECM to convey spatial
information about the position of the neighbor cells, so that the
stalk can elongates. In order to establish a bridge between another
vessels branch, other cells types (such as myeloid cells and
fibroblast, among other) have a role for establishing a functional
communication between neighbor vessels.
The final step in this process includes formation of functional
vessels becoming a stable tube in which permanent blood flow is
passing through. For endothelial cells to return to their quiescent
state and to get covered by pericytes again, several signals are
required including platelet-derived growth factor B (PDGF-B),
ANG-1, transforming growth factor-β (TGF-β), ephrin-B2, and
Notch. Protease inhibitors also participate at this stage-causing
establishment of basement membrane; while endothelial cells
form new tight junctions to avoid plasma extravasation and
ensuring optimal blood flow in the subrogating tissue (Carmeliet
and Jain, 2011; Carmeliet and Ruiz de Almodovar, 2013; see
Figure 1).
INSULIN AND INSULIN RECEPTORS
Insulin is synthesized by the beta cells of the islets of Langerhans.
This hormone has 2 dissimilar polypeptide chains, A and B,
linked by disulfide bonds. These two chains are derived from
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FIGURE 1 | Role of “tip” and “stack” cells on angiogenesis process. (A)
Release of angiogenic factors (which include VEGF, ANG-2, FGF, chemokines,
inflammatory, and tumor mediators) from hypoxic area (B). Activation of
endothelial cells in the microcirculation. Mural cells in the vascular wall (i.e.,
pericytes) are detached, while basement membrane is degraded. Protein
exudates form a provisional extracellular matrix scaffold where (C). Tip
endothelial cells start to migrate. Meanwhile, neighbor endothelial cells form
“stack cells.” (D) Formation of nascent new blood vessel. (E) Formation of
functional vessel as a stable tube in which permanent blood flow is passing
through.
a 1-chain precursor, proinsulin. Cytogenetic location of human
insulin is located in 11p15.5; which contains 3 exons; exon 2
encodes the signal peptide, the B chain, and part of the C-
peptide, while exon 3 encodes the remainder of the C-peptide and
the A chain (Steiner and Oyer, 1967). Insulin has far-reaching
metabolic consequences including control of circulating levels
of glucose, lipids and proteins. Also, circulating levels of insulin
are modulated by several hormones and circulating factors such
as amino acids, fatty acids, melatonin, estrogen, leptin, growth
hormone, among others (Fu et al., 2013). In mammals, insulin
also mediates mitogenic effects in a variety of cell types (Stout,
1991; Qiao et al., 2005; Simó et al., 2006; Shrader et al., 2009;
Heidegger et al., 2014). However, other reports have failed to find
an insulin-mediated endothelial proliferative response (Liu et al.,
2009; Lassance et al., 2013).
Differentially to human, in mice and rats, two non-allelic
insulin genes are present. Thus, a rodent specific Ins1 gene
that likely arose from the transposition of a reverse-transcribed,
partially processed mRNA of the ancestral Ins2 have been found
(Soares et al., 1985). Both genes reside in different chromosomes
with differential translational rates and protein function, as
showed in Ins1 or Ins2 deficient mice (see details in Templeman
et al., 2016). For instance, Ins1+/−:Ins2−/− male mice, but
not female littermates, were completely protected against diet-
induced obesity (Mehran et al., 2012). In a converse genetic
manipulation, Ins1−/−:Ins2+/− female mice (Templeman et al.,
2015), but not male littermates (Templeman et al., 2016), also
prevented obesity. Then, an intricate mechanism of regulation
and compensation between each of those genes were present
in Ins1 or Ins2 deficient male and female mice. Also, Ins1 and
Ins2 could differentially modulate receptor activity andmetabolic
consequences of this sex-specific Ins1/Ins2 effects. These are just
examples of how complex is the insulin regulation expression and
activity, a fact that is seldom considered in experimental animal
model studies.
In human, insulin activates tyrosine kinase receptor
expression on the surface of target cells, forming homo- or
heterodimers. In general, insulin binds to the insulin receptor
(IR), which has at least two isoforms. The first IR isoform lacks
exon 11 (exon 11-, IR-A), while the second isoform includes this
exon (exon +, IR-B) (see details in Templeman et al., 2016).
Insulin can also activate the family of insulin-like growth factor
receptors (IGF-IR), which in turn can form homodimers or
heterodimers with either IR-A or IR-B (Guzmán-Gutiérrez et al.,
2011; Hale and Coward, 2013). Additionally, the IGF-IR exhibits
a high level of homology with the IR. Therefore, insulin can
activate both families of receptors with different affinities. In
this review we will focus on IR-A and IR-B and will provide
references to excellent review articles for the study of IGF-IRs
(Hale and Coward, 2013).
IR-A is widely expressed throughout the body and is up-
regulated during prenatal development and in tumor cells
(Gennigens et al., 2006; Belfiore, 2007; Hale and Coward, 2013;
Heidegger et al., 2014). In contrast, IR-B is expressed in insulin-
sensitive tissues such as the liver, skeletal muscle and adipocytes
(Heni et al., 2012). It should be noted that both receptors are
expressed on endothelial cells (see details in Hale and Coward,
2013).
The insulin-activated intracellular pathways
[Phosphoinositide 3-kinase (PI3K), Mitogen-activated protein
kinase (MAPK) and Cbl-associated protein (CAP)] mediate at
least three major propagating responses (Westermeier et al.,
2011). In the next sections, we will summarize PI3K and MAPK
as part of insulin-mediated nitric oxide synthesis. However,
insulin also activates GTPase TC10 via lipid-raft localization of
the CAP-Cbl-Crk complex and the guanine nucleotide exchange
factor C3G, which then initiates glucose uptake (Hale and
Coward, 2013).
Overview of Insulin-Mediated PI3K
Signaling Pathway Activation
The PI3K pathway is one of the most characterized downstream
effectors of insulin and activates many of the metabolic functions
of this hormone. In brief, binding of insulin to IR triggers its
phosphorylation and activation of intrinsic kinase activity, which
in turn leads to tyrosine phosphorylation of insulin receptor
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substrate (IRS) proteins. Phosphorylation of IRS molecules
creates Src homology 2 (SH2) binding domains that serve as
docking points for SH2-containing proteins like PI3K and the
growth factor receptor-bound protein 2 (Grb-2) (see details
in Hale and Coward, 2013). The binding of PI3K to IRS-1
activates the catalytic subunit of PI3K, resulting in production
of phosphatidylinositol 3, 4, 5-trisphosphate (PIP3). PIP3
promotes phosphorylation and activation of 3-phosphoinositide-
dependent protein kinase-1 (PDK-1), which then activates
different serine/threonine kinases including Akt (see Muniyappa
et al., 2007; Manrique and Sowers, 2014; Manrique et al.,
2014). In the vascular field, insulin-mediated Akt activation in
endothelial cells leads to enhanced nitric oxide (NO) production
via both stimulation of L-arginine uptake and phosphorylation
of endothelial NO synthase on Ser1177 (activated eNOS) (see
Muniyappa et al., 2007; Manrique and Sowers, 2014; Manrique
et al., 2014).
Overview of Insulin-Mediated MAPK
Signaling Pathway Activation
Insulin-mediated activation of the MAPK pathway has been
linked with several cell functions including differentiation,
proliferation, transformation, survival, and death (Manrique
et al., 2014). In brief, this family of proteins consists of members
such as P38, extracellular-signal-regulated kinase (ERK), and c-
Jun-N-terminal kinase (JNK), with each of them exhibiting a
number of different isoforms (Hale and Coward, 2013). The
MAPK pathway is activated via a protein phosphorylation
cascade that includes Grb2-SOS-Shc-Gab1-SHP2 and Ras (Hale
and Coward, 2013). Interestingly, PI3K also binds Ras, producing
a cross-talk mechanism between the PI3K and MAPK pathways
(Taniguchi et al., 2006; Hale and Coward, 2013). In endothelial
cells, insulin-mediated activation of MAPK has been associated
with stimulation of L-arginine uptake and NO synthesis
(Rodriguez-Viciana et al., 1996).
The insulin-mediated intracellular pathway is far more
complex than described in these sections. However, conceptual
oversimplification considers twomajor signaling branches: PI3K-
dependent pathways that mediate the metabolic actions of
insulin and the MAPK-kinase-dependent pathway that mediates
the non-metabolic mitogenic and growth effects of insulin
(González et al., 2004, 2011). Furthermore, it has been described
that insulin-mediated IR-A activation is associated with a
MAPK/AKT (or PI3K) ratio > 1, which has been related
to a mitogenic pathway in mouse embryonic fibroblasts. In
contrast, insulin-mediated IR-B activation is associated with a
MAPK/AKT ratio < 1, which leads to activation of metabolic
signaling pathways (Muniyappa et al., 2007).
GENERAL OVERVIEW OF IN VIVO AND IN
VITRO EVIDENCE REGARDING INSULIN
AND ANGIOGENESIS
Insulin has pleiotropic effects on the vascular tree and in
particular, on endothelial cells. Therefore, it is not surprising
that insulin can modulate angiogenesis. Indeed, insulin has
TABLE 1 | Pathological vascularization in diseases related to insulin
alterations.
Vascularization defects References
Diabetes Reduced vascularization Escudero et al., 2014
mellitus • Impaired wound heling Martin et al., 2003
• Impaired recovery after
cardiac infarction
Liu et al., 2009; Kolluru et al.,
2012; Hrynyk and Neufeld,
2014
• Embryonic vasculopathy Chou et al., 2002; He et al.,
2006
• Transplant rejection Hattersley and Tooke, 1999
Hypervascularization
• Diabetic retinopathy Zhang et al., 2004; Cheng
et al., 2007
• Diabetic nephropathy Poulaki et al., 2002; Simó
et al., 2006; Kobayashi and
Puro, 2007; Meng et al., 2012
• Increased risk for cancer
Breast, colon, prostate,
kidney, pancreas
Chiarelli et al., 2000; Baelde
et al., 2004
Gestational
diabetes
Placental
hypervascularization
Belfiore, 2007; Giovannucci
et al., 2010
Obesity Hypervascularization of
adipose tissue
Escudero et al., 2013;
Lassance et al., 2013
Cancer Increased risk for prostate
cancer
Jung et al., 2012; Cao, 2013
been used for nearly 50 years to improve tissue healing in
rats (see details in Guzmán-Gutiérrez et al., 2011) and in both
diabetic and non-diabetic mice (Gregory, 1965). Additionally,
preterm mice lacking insulin receptors in vascular endothelial
cells exhibit reduced retinal neovascularization compared to
controls (Rosenthal, 1968). Furthermore, diseases associated with
altered insulin production and action such as diabetes and
obesity exhibit impaired angiogenic processes that are related to
microvascular alterations and the pathogenesis of those diseases.
We refer to Table 1 and the Section Pathological Implication of
Insulin-Mediated Angiogenesis of this manuscript for additional
analysis. Briefly, we mentioned that IRs are highly expressed
in normal- and cancer-derived endothelial cells (Kondo et al.,
2003) and that the activation of these receptors has been
related to cell migration, proliferation, endothelium survival,
and VEGF expression during tumor angiogenesis. Additionally,
insulin receptors are expressed in pericytes (contractile cells
that wrap around the endothelial cells) in which they modulate
endothelium-pericyte interaction, a fundamental step for vessel
maturation (Liu et al., 2009; Rensing et al., 2010; Westermeier
et al., 2011).
Insulin analogs such as arg-insulin exhibit high pro-
proliferative activity in human osteosarcoma cells with a potency
at least 8 times greater than human insulin (Hale and Coward,
2013). Additionally, insulin resistance and hyperinsulinemia may
promote tumor angiogenesis and tumor development directly
through activation of insulin receptors or indirectly by increasing
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the levels of insulin-like growth factors (IGF), steroid sex
hormones, inflammatory processes, and by disrupting adipokine
homeostasis (Kurtzhals et al., 2000). Insulin and insulin analogs
also show high capacity to stimulate angiogenesis in vitro (Jalving
et al., 2010). In contrast, metformin, an insulin-sensitizing
drug, reverts increased levels of VEGF, angiopoietin-like protein
(ANGPTL 1), and the ANGPTL 1/ANGPTL 2 ratio, as well as
decreased levels of platelet-derived growth factor B (PDGFB)
and platelet-derived growth factor D (PDGFD) observed in
hyperinsulinemic animals (Rensing et al., 2010). Therefore,
metformin may have anti-angiogenic properties (Di Pietro et al.,
2015).
Insulin, directly or indirectly, has been linked with angiogenic
processes. In the next sections, we will discuss evidence that
supports a direct pro-angiogenic role of insulin on endothelial
cells, on the synthesis and release of pro-angiogenic factors, and
on endothelial-pericyte interactions.
INSULIN AND PERICYTES
Pericytes are a class of mural cells that provide support to blood
vessels of all sizes. Conventionally, they have been described as
a component of smaller vessels such as capillaries, arterioles,
and venules. Although pericytes were originally thought to act
as support cells, they actually participate in vessel contraction
by regulating vascular diameter and capillary blood flow.
Pericytes also control endothelial membrane folding and luminal
cytoplasmic protrusions. These cells establish active cross-talk
with endothelial cells that promote endothelial cell differentiation
and maturation (see details in Viollet et al., 2012). Pericytes
also have been linked with the maintenance of endothelial
survival and the inhibition of endothelial cell migration and
sprouting processes through VEGF expression and also serve
as multilineage progenitor cells (see details in Richards et al.,
2010). Therefore, pericytes normally play a role in adjusting the
angiogenic process, and pericyte loss or dysfunction has been
noted in the earliest phase of diabetic retinopathy (see details in
Richards et al., 2010).
The initial description of IR expression on human pericytes
was reported in the 80s (Kobayashi and Puro, 2007). Using
125I-radiolabelled insulin and binding experiments, high affinity
receptors, similar to those identified on retinal endothelial
cells, were characterized on pericytes (James and Cotlier, 1983).
Interestingly, insulin was more effective for enhancing cell
proliferation of pericytes than endothelial cells (King et al., 1983).
More recent evidence have shown that insulin treatment for
glycaemia reduction in diabetic patients was associated with an
elevated number of circulating pericyte progenitor cells after
3 months of treatment (King et al., 1983). Therefore, IRs are
present in pericytes and appear to enhance pericyte proliferation
and mobilization of pericyte progenitor cells from bone marrow.
The functionality of IRs on pericytes has been studied
using cells isolated from bovine retinal capillaries, in which
insulin induced a slow hyperpolarization in a dose-dependent
manner (Fadini et al., 2012). Further characterization analyses
revealed the participation of both Kir and small-conductance
Ca2+-sensitive potassium channels in the insulin-induced
hyperpolarization of these cells. Kobayashi and Puro (Berweck
et al., 1993) used normal rat retina to show that insulin-reduced
endothelial cell death occurs only in microvessels that contain
pericytes, an effect that was associated with PI3K and ERK
activation.
Despite limited information about the direct role of insulin
on pericyte function during angiogenesis, it has been shown
that insulin protects human brain pericytes from the toxic
effect of beta amyloid mimic Abeta1-40 in a dose-dependent
manner (2007). Thus, insulin could protect cerebral tissue
from damage during Alzheimer disease by inducing pericyte
survival and vascular recovery. More studies are needed to
clarify the significance of insulin effects on pericyte-endothelium
interaction or angiogenesis (see Figure 2).
INSULIN AND ENDOTHELIUM
Studies of angiogenesis in vitro have examined cell proliferation,
cell migration, tube formation capacity, expression and/or
activation of pro-angiogenic factors such as VEGF and VEGF
receptor (VEGFR). Effects of insulin on these parameters are
summarized in Figure 3.
Insulin increased endothelial cell migration in a manner
that was not blocked by VEGFR type 2 (VEGFR2) inhibitor
SU1498 (Rensink et al., 2004). Further characterization of that
phenomenon showed that insulin-mediated migration required
participation of PI3K, Akt-sterol regulatory element-binding
protein-1 (SREBP-1) and Ras-related C3 botulinum toxin
substrate 1 (Rac-1) (Liu et al., 2009). Afterward, insulin could
induce a VEGF-independent mechanism involving activation of
the PI3K-Akt-SREBP-1-Rac1 pathway, leading to cell migration.
In terms of tube formation or in vitro angiogenesis, Lassance
et al. (2013) showed that insulin enhanced in vitro angiogenesis
and caused actin reorganization. This effect was associated with
phosphorylation of IR and IRS-1, as well as Akt, glycogen-
synthase kinase-β3 and endothelial NOS (eNOS). This in turn
caused increased nitric oxide (NO) production and activation of
Rac1.
Insulin also stimulated cell proliferation in several cell lines
or primary cultures including arterial smooth muscle, fibroblasts,
and epithelial cells (Lassance et al., 2013). However, the effect
of insulin on endothelial cell proliferation is still controversial.
Several studies reported an increase in proliferation (Stout, 1991;
Jiang et al., 2003), while other studies reported no effect (King
et al., 1983; Yamagishi et al., 1999; Liu et al., 2009; Shrader
et al., 2009) compared to untreated cells. In this regard, insulin
increased the area occupied by CD31+ or endothelial cells and
the formation of mature blood vessels (identified by pericyte
coverage) in a rat model of subcutaneous healing (Nagai et al.,
2003; Liu et al., 2009). King et al. (1983) also showed that
microvascular endothelium isolated from calf retina exhibited
a dose-dependent increase in cell proliferation in the presence
of insulin (1–1,000 nM), whereas endothelium derived from
calf aorta showed no such effect. This differential response
was observed only with insulin because other stimuli such as
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FIGURE 2 | Insulin-mediated pericyte and endothelial cell-to-cell interaction during angiogenesis. As described in this manuscript, few reports have
analyzed the potential role of insulin in the endothelial-pericyte interactions during cell proliferation/migration or vessel maturation. The molecular mechanisms
summarized in this schematic representation indicate that on endothelial cells, insulin, either directly or via vascular endothelial growth factor (VEGF) expression, is
involved in promoting angiogenesis. Insulin also activates insulin receptors present on pericytes leading to survival and proliferation of these cells. In pericytes, insulin
induces expression of VEGF, which might reach its respective receptors on the endothelial cell surface and control endothelial survival. Alternatively, insulin can
activate mobilization of progenitor cells (PC), which might differentiate into either pericytes or endothelial cells. Until now it is unknown whether insulin uses
transcellular or paracellular transport mechanisms in endothelial cells to reach the subendothelial space and then activate insulin receptors on pericytes.
serum or endothelial growth factors induced similar proliferative
responses in both endothelial cell types. The differences can be
attributed to the fact that micro- and macro-vascular endothelial
cells can respond to insulin differentially (1983).
INSULIN AND VEGF
The proliferative response mediated by insulin has been
associated with higher VEGF levels in some endothelial cell types.
For instance, insulin-induced proliferation of human umbilical
vein endothelial cells (HUVEC) was associated with activation
of PI3K, Akt, and up-regulated VEGF protein expression (King
et al., 1983; Lang et al., 2003; Sobrevia et al., 2011). The
latter effect was confirmed by other reports involving human
microvascular endothelial cells in which insulin increased VEGF
mRNA levels (Shrader et al., 2009) or extracellular protein levels
of VEGF (Yamagishi et al., 1999).
The underlying pathway for insulin-mediated expression
of VEGF depends on several conditions including cell type,
time and doses of incubation. Thus, insulin increased VEGF
expression via p38 mitogen-activated protein kinase (MAPK)
and PI3K, but not via p42/p44 MAPK or PKC pathways in
retina of diabetic rats (Liu et al., 2009). Jiang et al. (2003)
confirmed that insulin enhanced VEGF mRNA levels in a
time- and dose-dependent manner with biphasic behavior in
aortic smooth muscle cells. Accordingly, in this model, a rapid
phase (100 nM, 1 h) for insulin-mediated VEGF expression
depended solely on PI3K activation, whereas a second phase
(12 h) depended on both PI3K and p42/p44 MAPK pathways.
Nevertheless, in cardiomyocytes isolated from neonates and
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FIGURE 3 | Summary of insulin actions in angiogenesis. Insulin receptor activation leads to endothelial cell survival, differentiation and growth via activation of
MAPKs. Additionally, insulin receptor activation leads to nitric oxide (NO) synthesis via PI3K-AKT activation, which in turn regulates endothelial survival, migration,
proliferation, and vascular permeability. Additionally, NO may regulate the expression of vascular endothelial growth factor (VEGF), but the molecular mechanisms that
underlie this effect are still unclear. Alternatively, insulin mediates a pro-angiogenic effect by expression and secretion of VEGF, which then can activate VEGF receptors
(mainly VEGFR2), leading to activation of phosphorylation cascades including cross-talk (dashed lines) between insulin-mediated PI3K and endothelial nitric oxide
synthase (eNOS) or by directly activating MAPKs generation of pro-angiogenic effects on endothelial cells.
adult rats, it has been shown that insulin increased VEGF
mRNA and protein expression in the culture medium in a
dose-dependent manner (0–250 nM). To increase the levels of
VEGF expression, insulin requires the PI3K/Akt pathway, but
not the Ras/MEC/Erk-1/2 pathway in this cell type. Further
characterization in cardiomyocytes found that insulin-mediated
VEGF expression requires Akt2, but not Akt1 (2003).
In vivo experiments also have confirmed insulin-mediated
expression of VEGF. Insulin was found to enhance VEGF and
VEGFR1mRNA levels without changes in VEGFR2mRNA levels
in a rat model of hepatic regeneration after partial hepatectomy
(He et al., 2006). In the same model, protein levels of VEGF also
increased at 72 h after insulin treatment (Qiao et al., 2005). In
streptozotocin-induced diabetic rats, the level of VEGF mRNA
expression was increased, whereas the VEGFR1 mRNA level
was unaltered in aortas from insulin-treated diabetics (5–30
U/Kg/day for 1 week) compared to either untreated diabetics or
non-diabetics treated with insulin (Qiao et al., 2005).
Amore direct analysis regarding the physiological significance
of IRs and their signaling pathways in VEGF expression
and vascularization was performed using hearts from muscle-
specific insulin receptor knockout (MIRKO) mice. In these
studies, insulin injection (5 U/Kg) in MIRKO animals reduced
Akt activation, VEGF mRNA levels, and expression of the
endothelial cell marker, VE-Cadherin (Kobayashi and Kamata,
2002). Furthermore, in this study, the authors evaluated the level
of vascularization in the peri-infarct zone from ventricular tissues
of MIRKO and control mice at 7 days after coronary artery
ligation. Their results showed a high mortality rate in MIRKO
animals, which was associated with reduced blood vessels in
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the peri-infarcted zone without changes in endothelial cell
proliferation. Therefore, these results showed that the insulin-
PI3K/Akt2-VEGF pathway is a key factor in the recovery of
vascularization after myocardial ischemia.
Insulin and Placental Growth Factor
The placental growth factor (PLGF), which belongs to the family
of VEGF factors, has also been associated with angiogenesis.
In this regard, ARPE-19 cells exposed to hypoxic conditions or
to insulin induced an up-regulation of PLGF expression (He
et al., 2006). Considering this effect, insulin, via PLGF up-
regulation, might control endothelial cell permeability, which
in turn activates the PLGF-mediated ERK signaling pathway.
These effects resulted in the opening of the retinal pigmental
endothelium tight junctions, and consequently, have been
involved in retinal edema (Miyamoto et al., 2007).
INSULIN AND ANGIOPOIETINS
Angiopoietin (Ang) and Tie receptor tyrosine kinases (Tie)
constitute another family of proteins that are almost exclusively
expressed in endothelial cells (Miyamoto et al., 2007). In humans,
Ang1, Ang2, and Ang4, which bind Tie1 and Tie2 receptors,
constitute this family of proteins. The activation of these
receptors has been linked to vessel quiescence in adults, as well
as the regulation of vascular remodeling and maturation of blood
and lymphatic vasculature during later phases of embryonic
and postnatal development (Eklund and Saharinen, 2013). Ang1
functions as a Tie-2 agonist, whereas Ang2 is a natural inhibitor
of the Tie-2 receptor that antagonizes the Ang1-specific vascular
protective function (Eklund and Saharinen, 2013). Because the
ligand for Tie-1 has not been identified, this orphan receptor may
act as a negative regulator of Tie-2; however, its precise role is
still unclear (Rasul et al., 2012). Additionally, the activation of
Tie-2 receptors by Ang1 drives a negative-feedback loop for Ang2
production on endothelial cells (Augustin et al., 2009; Carmeliet
and Jain, 2011); therefore, Ang-Tie is a highly self-controlled
system.
Very little is known about the interaction between insulin
and angiopoietins. However, the relationship between these two
main regulators is indirectly manifested in patients with type
2 diabetes mellitus (T2DM). Previous observations, including a
large third-generation cohort of the Framingham Heart Study,
showed a positive association between circulating Ang-2 levels
and the occurrence of diabetes, but an inverse relationship with
total cholesterol and diastolic blood pressure (Daly et al., 2004).
Meanwhile, soluble Tie-2 was positively associated with body
mass index and triglycerides (Lieb et al., 2010). Unfortunately, no
analyses of insulin administration were performed in this study.
Additionally, in a case-control study, Li et al. (2015)
found that serum Ang-2 levels present in T2DM patients
with angiopathy were significantly higher compared to patients
without angiopathy (Lieb et al., 2010). Furthermore, Ang-
2, but not Ang-1, levels were positively correlated with a
homeostasis model assessment for insulin resistance (HOMA-
IR) and glycosylated hemoglobin A1c (HbA1c). This indicates
that Ang-2 may constitute a marker of dysfunctional angiogenic
process in these patients.
On the other hand, angiopoietin-like proteins (ANGPTL) are
orphan ligands (at least 7 members) that have similar structure
domains to angiopoietins but do not bind to Tie-1 or Tie-2
receptors. From these proteins, ANGPTL-1-4 and ANGPTL-
6 are functionally expressed in endothelial cells and control
survival and migration-inducing signals leading to angiogenesis.
To the contrary of what was proposed for Ang1, ANGPTLs
are synthesized not only in endothelial cells but also in many
other cell types. Furthermore, ANGPTL2, 3, 4, and 6 molecules
can be detected in the circulation (Li et al., 2015). Additionally,
Tie-2-mediated activation of PI3K has been associated with
cell migration (see details in Augustin et al., 2009), three-
dimensional capillary organization, proliferation, and increased
expression of basement-membrane-degrading proteases (Master
et al., 2001). Also, ANGPTLs may regulate lipid, glucose and
energymetabolism (see details in Augustin et al., 2009). However,
as far as we know, there is no information regarding the potential
role of insulin on ANGPTL-mediated angiogenesis.
PATHOLOGICAL IMPLICATION OF
INSULIN-MEDIATED ANGIOGENESIS
Diabetes Type 1 and Type 2 and
Angiogenesis
Since type 1 (T1DM) and type 2 (T2DM) diabetes are
pathophysiologically different diseases, it is expected that
vascular complication will also be different. For instance
macroangiopathy occurs more frequently in type 2 diabetes,
while microangiopathy is a common feature of both types
of diabetes. In terms of angiogenesis, in T1DM and T2DM,
there are two tissue-specific paradoxical changes in small blood
vessels in diabetes (Simons, 2005). One is an excessive, and
uncontrolled formation of premature blood vessels in some
tissues such as the retina, in which neovascularization is a
hallmark of late-stage diabetic retinopathy and atherosclerotic
plaque destabilization. The other is the deficiency in the
formation of small blood vessels in peripheral tissues such as
the skin, which contributes to the impaired wound healing in
the skin, fibrosis and deficiency in collateral vessel development.
Therefore, in diabetes, angiogenesis can be up regulated or down
regulated, depending of duration of disease and compliance in
the metabolic control (Nentwich and Ulbig, 2015).
Regarding differences in angiogenesis in T1DM and T2DM,
Yan et al. (2009) evaluated postischemic neovascularization in
streptozotocin-treated (type 1 diabetes model); type 2 diabetic
Lepr(db/db) and control mice. They found that postischemia
recovery of hind limb perfusion was less in T2DM than T1DM
mice. Also, they found a reduced endothelial progenitor cell
incorporation into tubular structures in T2DM mice. They
concluded that T2DMmice displayed a significantly less effective
angiogenic response to ischemia than T1DMmice.
Preclinical studies also have found an impaired VEGF-
induced migration in marrow-derived EPCs from T1DM and
T2DM, as well as impaired incorporation of EPCs into tubular
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structures that was less effective in T2DM than T1DM rodents
(Yan et al., 2009). These results suggest an impairment of
EPC mobilization and function; therefore processes such as
vasculogenesis and/or endothelial repair might be differentially
affected in T1DM and T2DM.
In human, previous results also suggest a differential
angiogenesis process in T1DM and T2DM patients. For instance,
VEGF-A was most intensely present in vitreous samples
and neovascular tufts from T1DM patients with proliferative
retinopathy. While, VEGF-D was more abundant in T2DM
than T1DM patients (Kinnunen et al., 2009). Also, differential
sequence variations in the VEGFA gene were associated with
elevated risk for developing blinding diabetic retinopathy in
T1DM and T2DM patients (Abhary et al., 2009). Thus, after
controlling for sex, HbA1c, and duration of disease, in T1DM,
the AA genotype of rs699946 and the GG genotype of rs833068
were most significantly associated; while in T2DM, the C
allele of rs3025021 and the G allele of rs10434 were most
significantly associated with blinding diabetic retinopaty. How
these differences may impact the pathophysiology of diabetic
retinopathy or angiogenesis process in general are still unknown.
Microvascular Dysfunction in the Diabetic Retina
According to the evolution of the clinical diabetes, after 20 years
of having this disease, almost all T1DM patients, 80% of insulin-
dependent diabetes patients, and 50% of insulin-independent
T2DM patients will have vision loss due to diabetic retinopathy
(Chou et al., 2002). Globally, the prevalence of diabetic
retinopathy is estimated to be 126 millions of the 382 million
people with diabetes (Zheng et al., 2012). Clinically, diabetic
retinopathy has two forms: nonproliferative diabetic retinopathy
(NPDR) and proliferative diabetic retinopathy (PDR), which in
turn is related to absence or presence of neovascularization,
respectively.
The pathophysiology of diabetic retinopathy (DR) is complex
and multifactorial. Endothelial dysfunction has been recognized
as a key factor and includes capillary basement membrane
thickening, damage of vascular wall structure with endothelial
cell and pericytes loss associated with impairment of blood-
retinal barrier, and increased neovascularization (mainly due to
angiogenesis) (Dhoot and Avery, 2016). Thus, diabetic patients
exhibit an enhanced angiogenic process that contributes to
DR, nephropathy and atherosclerotic plaque destabilization
(Martin et al., 2003). Additionally, epidemiological studies have
shown that insulin therapy is an independent risk factor for
the progression of intraocular neovascularization in diabetic
retinopathy (Martin et al., 2003). Therefore, angiogenesis is a key
factor in the generation and/or progression of vascular alterations
in diabetes.
In terms of neovascularization, dysfunction of endothelial
progenitor cells (EPC) has been reported in patients with
T1DM and T2DM (see details in Lois et al., 2014). However,
determination of the number of circulating EPC in diabetic
patients has evidenced conflicting results, not only considering
T1DMor T2DM, but also according to severity of the disease.We
would like to refer the excellent review by Lois and colleagues (see
details in Lois et al., 2014).
Multiple studies have identified VEGF as a key factor in
the pathogenesis of DR in particular PDR (Yu et al., 2016).
For instance, a positive correlation among patients with poor
glycemic control and increased VEGF plasma levels has been
found (Zehetner et al., 2013), while high VEGF levels were found
in aqueous and vitreous with PDR in comparison with NPDR
(Dhoot and Avery, 2016; Mohamed et al., 2016). In accordance
with this mechanism, anti VEGF therapy has been tested in
clinical trials in a small number of PDR patients with some
promissory effects (Dhoot and Avery, 2016; Mohamed et al.,
2016).
Diabetes, Healing, and Angiogenesis
Diabetes mellitus is a disease associated with impaired
neovascularization that leads to reduced revascularization
of ischemic tissues; impaired wound healing; embryonic
vasculopathy and organ transplant rejection in diabetic patients
(Oike et al., 2005). Impaired wound healing is also referred
to as chronic wound including slow healing and non-healing
wounds. Re-epithelialization and angiogenesis are two essential
steps in wound healing. Since, wound healing is delayed in the
presence of high levels angiogenic inhibitors, and promoted
by local administration of VEGF (Barrientos et al., 2014), it
is not surprising that this marker has been linked to impaired
wound healing process observed in diabetic patients. Indeed,
recombinant VEGF applied topically to chronic diabetic
neuropathic foot ulcer, three times a week for up to 6 week,
reduced in at least 10 days the ulcer healing in diabetic patients
(Hanft et al., 2008).
Nonetheless, little information has been found regarding the
angiogenic role of insulin in diabetic subjects. For instance,
insulin administration enhanced VEGF in cardiomyocytes
isolated from diabetic rats (Simó et al., 2006) and reduced
circulating anti-angiogenic proteins (angiostatin and endostatin)
in Yucatan miniswine (Chou et al., 2002). In humans, diabetes
and insulin resistance have been associated with reduced VEGF
expression in the heart, which may decrease capillary density
in the myocardium of diabetic and insulin-resistant patients
(Boodhwani et al., 2007). Insulin use has also been associated with
some specific cancers (see below). However, more information is
required to better understand the impact of insulin treatment in
diabetic patients.
Cancer, Diabetes, and Insulin-Mediated
Angiogenesis
Insulin as a growth factor has been linked with tumor growth
in prostate (Aiello et al., 1994) and breast cancers (Heni et al.,
2012), among others. Epidemiological evidence has also shown
that patients with T2DM have increased risk for breast, colon,
prostate, kidney, and pancreatic cancers (Belfiore, 2007; Huang
et al., 2011; Kalla Singh et al., 2011), an effect that has been
associated with high insulin plasma levels (Giovannucci et al.,
2010). Accordingly, T2DM patients who used insulin analogs
such as glargine exhibited a high risk of cancer in a dose-
dependent manner (adjusted hazard ratio was 1.1, 1.2, and
1.3 for daily doses of 10, 30, and 50 U, respectively) (Jalving
et al., 2010). On the other hand, T2DM patients who were
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treated with metformin, an insulin sensitizer, showed a reduced
risk of cancer (odds-ratio for any exposure to metformin was
0.79) (Hemkens et al., 2009; Grouven et al., 2010; Rensing
et al., 2010). Additionally, Evans et al. (2005) and Jalving et al.
(2010) found an inverse dose-response relationship between
duration of exposure to metformin and cancer incidence. Also,
reduced incidence of neoplastic diseases and cancer mortality in
T2DMpatients treated with metformin has been reported (2005).
Interestingly, reduction in the relative risk seems to be specific to
certain cancers such as prostate, pancreas and breast cancers (see
Table 1).
The mechanisms for the angiogenic role of insulin-sensitizing
drugs on cancer development are not well understood. However,
the role of IRs seems to be noticeable. On this regard,
overexpression of IR-A, but not IR-B, has been linked to increased
proliferation and migration in prostate cancer and non-cancer
cell lines (see details in Viollet et al., 2012). Interestingly, using
chorioallantoid membrane assays, Heidegger et al. (2014) have
shown that a prostate cancer cell line (PC3) overexpressing
IR-A and seeded on chorioallantoid membranes exhibited higher
tumor growth compared to control. Complementarily, tumor
vascularization was enhanced in tumors generated by cancer
cells overexpressing IR-A. However, this effect was reduced in
cancer cells in which IR-B expression was down regulated. This
effect indicates participation of both receptors in angiogenesis of
prostate cancer.
Obesity, Insulin, and Angiogenesis
Preadipocytes have endothelial and perivascular origins,
suggesting that adipogenesis, angiogenesis, and vascular
remodeling are tightly and coordinately regulated (Heidegger
et al., 2014). Additionally, the histological appearance of
adipose tissue remains a “honeycomb-like” structure in which
each adipocyte is embedded in a vascular chamber. On the
other hand, adipose tissue expansion was associated with
compensatory increased vasculature that resembles tumor
growth. Interestingly, this phenomenon is related to insulin
resistance (Cao, 2013). Except for the findings of these studies,
the role of the vascular network on adipocyte function is not
completely understood. Indirect evidence shows that decreased
blood supply leads to hypoxia and inflammation in obese
people. This exacerbates insulin resistance (Cao, 2013) but can
also stimulate angiogenesis (Cao, 2013). Adipose angiogenesis
reduces adipose tissue hypoxia and fibrosis. Therefore, it is
expected that more vascular endothelial cells in adipose tissue
can mitigate the effects of insulin resistance in obese or diabetic
patients (Ahmed et al., 2000). However, how insulin resistance
generated during obesity might impact adiposity-mediated
angiogenesis remains unclear.
Classically, it has been identified the muscles, liver, and
adipose tissue as the major targets for insulin resistance.
Also, vascular cells, and in particular endothelial cells are
selectively affected by insulin resistance. This is important,
since endothelial monolayer is the first cell type encountered
during insulin delivery and may contribute to tissue specific
affection of angiogesis. Regarding adipose tissue, visceral adipose
tissue (VAT) is more closely linked to insulin resistance than
subcutaneous adipose tissue (SAT). Thus, they are metabolically
different, and angiogenesis could be differentially affected in
those tissues. In this regards, near to 50% of the adipose tissue,
particularly VAT, secretome was composed of factors with a
role in angiogenesis (Hocking et al., 2010). However, as far as
we known, literature lack of information about tissue specific
affection of angiogenesis in the frame of insulin resistance.
CONCLUDING REMARKS AND FUTURE
DIRECTIONS
Insulin, as a hormone involved in tissue growth and recovery
after injury, is involved in the control of angiogenesis through
at least four mechanisms reviewed in this article: (1) control
of the interaction between endothelium and pericytes; (2)
endothelial cell migration and proliferation (particularly in
microcirculation); (3) synthesis of pro-angiogenic factors such as
VEGF and Ang; and (4) regulation of tissue metabolism, which
indirectly affects endothelial cell survival. Despite the fact that
these effects are well described in the literature, the underling
signaling pathways are not entirely known.
In particular, functional expression of IR-A and IR-B have
been described on endothelial cells and pericytes, which trigger
intracellular signaling involving PI3K and MAPK pathways,
as well as subsequent activation of phosphorylation cascades
that lead to synthesis of pro-angiogenic factors such as VEGF
and Ang. These mechanisms result in modulation of cell
migration, cell proliferation, in vitro angiogenesis, endothelial
differentiation and survival. Because angiogenesis involves all
of these effects, the general agreement is that insulin is a pro-
angiogenic hormone. It is not clear, however, whether all of these
effects are triggered in all endothelial or vascular cells.
These mechanisms become uncertain when considering,
for example, which type of insulin is being used (natural
or pharmaceutical preparation), or whether insulin-sensitizing
drugs are used. Further complexity should be analyzed
considering which IRs are present in any specific endothelial
cell type (macrovascular or microvascular endothelium). On this
regard, future analyses should consider that not only IRs, but
also VEGFRs, are differentially expressed on endothelial cells.
More specifically, future investigations should consider which
specific tyrosine is phosphorylated during VEGFR2 activation,
because differential cell responses can be triggered accordingly
(Jung et al., 2012). Moreover, future studies should be designed
considering that intracellular pathways associated with either
insulin or VEGF exhibit active cross-talk inside the cells. Lastly,
we could not rule out the participation of IGFs and IGFRs in
many, if not all, of the angiogenic mechanisms discussed in this
article.
Pathological implications of these mechanisms in T2DM,
cancer or obesity are even less known. We highlighted
in this article the case of T2DM or insulin resistance, in
which a reduction of insulin activity led to microvascular
alterations (in skin, eye, kidney, and neurovascular tissues,
among others). It also seems to be evident that recovery of
insulin effects by either pharmacological use of insulin or by
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using insulin-sensitizers would help to prevent the occurrence of
microvascular alterations in diabetes. However, epidemiological
analyses have shown that T2DM patients under glycemic control,
in particular, those who use insulin analogs, have at least a
30% higher risk for developing cancer in breast, colon, prostate,
kidney and pancreas tissues. Clinical and basic scientists should
be aware of this information and conduct future investigations to
clarify the mechanisms behind the relationship between cancer
risk and use of insulin analogs.
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